The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment

Summary

Recent studies have described the role of melatonin as a sleep regulator and as an anti- oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in Alzheimer's disease (AD). In accordance with this data, our hypothesis is that melatonin will delay the cognitive decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI to AD.

Timeline

Start

2007-10

Primary completion

—

Completion

2010-10

Drugs

Indications